EX-99.2

Endo and Auxilium:

October 9, 2014

A Compelling Business

Combination

Exhibit 99.2

Additional Information

ADDITIONAL INFORMATION

This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. This communication relates to a proposed

business combination transaction between Endo International plc ("Endo") and Auxilium Pharmaceuticals, Inc. ("Auxilium"). In furtherance of

this proposed transaction, Endo and Auxilium intend to file one or more registration statements, prospectuses, proxy statements or other

documents with the U.S. Securities and Exchange Commission ("SEC"). This communication is not a substitute for any registration statement,

prospectus, proxy statement or other document Endo and/or Auxilium file with the SEC in connection with the proposed transaction. INVESTORS

AND SECURITY HOLDERS OF AUXILIUM ARE URGED TO READ THE REGISTRATION STATEMENT, PROSPECTUS, PROXY STATEMENT AND OTHER

DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT

INFORMATION ABOUT THE PROPOSED TRANSACTION. The definitive proxy statement (when available) will be mailed to stockholders of

Auxilium. Investors and security holders will be able to obtain free copies of these documents (when available) and other documents filed

with the SEC by Endo through the web site maintained by the SEC at

http://www.sec.gov.

CERTAIN INFORMATION REGARDING PARTICIPANTS

Endo and Auxilium and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies

from Auxilium stockholders with respect to the proposed transaction under the rules of the SEC. Security holders may obtain information

regarding the names and interests of Endo's directors and executive officers in Endo Health Solutions Inc.'s ("EHSI") Annual Report on Form 10-K

for the year ended December 31, 2013, which was filed with the SEC on March 3, 2014, and Endo's proxy statement for the 2014 Annual General

Meeting of Shareholders, which was filed with the SEC on April 29, 2014. Security holders may obtain information regarding the names and

interests of Auxilium's directors and executive officers in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2013, which

was filed with the SEC on February 28, 2014, Auxilium's proxy statement for the 2014 Annual Meeting of Stockholders, which was filed with the

SEC on April 10, 2014, and the materials that will be filed with the SEC in connection with the proposed transaction. These documents can be

obtained free of charge from the sources indicated above. Additional information regarding the interests of these participants in the proxy

solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the proxy statement

and other relevant materials to be filed with the SEC when they become available.

All trademarks, service marks, trade names, product names and logos appearing in this presentation are the property of their respective

owners. XIAFLEX®, Testim®, TESTOPEL®, STENDRA®, edex®, Osbon® ErecAid®, STRIANT®, Theo24®, Semprex®-D, dilatrate®-SR and robaxin® and

the related logos are the property of Auxilium. All other trademarks, service marks, trade names, product names and logos appearing in this

presentation are the property of Endo

Forward-Looking Statements

This communication may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities

legislation. These forward-looking statements include, but are not limited to, statements regarding the proposed transaction, the financing of the proposed

transaction, Endo's and Auxilium's expected future performance (including expected results of operations and financial guidance), and the combined company's

future financial condition, operating results, strategy and plans. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates,"

"plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect Endo's

and Auxilium's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Although Endo and

Auxilium believe that these forward-looking statements and information are based upon reasonable assumptions and expectations, readers should not place undue

reliance on them, or any other forward looking statements or information in this communication. Investors should note that many factors, as more fully described in

the documents filed by Endo with the SEC and with securities regulators in Canada on the System for Electronic Document Analysis and Retrieval ("SEDAR"), and by

Auxilium with the SEC, including under the caption "Risk Factors" in EHSI's Form 10-K and Endo's Form 10-Q and Form 8-K filings, and in Auxilium's 10K, 10-Q and 8-K

filings, as applicable, and as otherwise enumerated herein or therein, could affect future financial results and could cause actual results to differ materially from those

expressed in forward-looking statements contained in this communication. Important factors that, individually or in the aggregate, could cause actual results to differ

materially from expected and historical results include, but are not limited to:

•

the failure to receive the required approval from Auxilium stockholders and applicable government and regulatory authorities (and the terms of those approvals)

•

the risk that a condition to closing contemplated by the merger agreement may not be satisfied or waived;

•

the ultimate outcome and results of integrating the operations of Endo and Auxilium, the ultimate outcome of Endo's operating strategy applied to Auxilium and

the ultimate ability to realize synergies and the magnitude of such synergies;

•

the effects of the business combination of Endo and Auxilium, including the combined company's future financial condition, operating results, strategy and plans;

•

Endo's ability to achieve significant upside potential for shareholders by accelerating the growth of XIAFLEX® and other products of the resultant combined

company;

•

Endo's ability to sustain and grow revenues and cash flow from operations in its markets and to maintain and grow its customer base, the need for innovation and

the related capital expenditures and the unpredictable economic conditions in the United States and other markets;

•

the impact of competition from other market participants;

•

the development and commercialization of new products;

•

the effects of governmental regulation on our business or potential business combination transaction;

•

the availability and access, in general, of funds to meet Endo's debt obligations prior to or when they become due and to fund its operations and necessary capital

expenditures, either through (i) cash on hand, (ii) free cash flow, or (iii) access to the capital or credit markets; and

•

Endo's ability to comply with all covenants in its indentures and credit facilities, any violation of which, if not cured in a timely manner, could trigger a default of its

other obligations under cross-default provisions.

All forward-looking statements attributable to Endo or Auxilium or any person acting on either of their behalf are expressly qualified in their entirety by this

cautionary statement. These forward-looking statements speak only as of the date hereof. Neither Endo nor Auxilium assumes any obligation to publicly update any

forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities law.

Transaction Summary

Endo to acquire Auxilium Pharmaceuticals for $33.25 per share in

cash and stock

Represents a 55% premium to Auxilium’s closing price on September 16, 2014

Implies transaction value of approximately $2.6 billion, including the assumption of debt

Unanimously

approved

both

companies’

Boards

Directors

Creates leading specialty healthcare company with expanded platform for future

growth

Significant opportunity for value creation

Expected to be immediately accretive post close

Provides expected annual run rate synergies up to $175 million by the first year after closing

versus Auxilium’s trailing 12-month actuals as of June 30, 2014

Synergies include Auxilium’s $75 million reduction in annual operating expenses previously

announced

Expected closing in the first half of 2015, subject to regulatory approval and other

customary closing conditions

Expected

significantly

enhances

Endo's

branded

pharmaceutical

business

with

the

addition of Auxilium's leading men's health products and development portfolio

Designed to accelerates growth and maximizes value of Auxilium’s products by

leveraging strengths of combined company

Enhance the long-term organic growth for combined branded pharmaceutical business

Expand R&D capabilities and development programs

Compelling Strategic and Financial Rationale

Creating benefits for both Endo and Auxilium shareholders,

as well as for patients, customers and employees

Generates significant synergy opportunities in addition to Auxilium’s announced

restructuring

Creates company with enhanced financial flexibility, proven M&A platform and

established corporate structure

Aligned with Endo’s strategy of pursuing accretive, value creating growth

opportunities

Transaction At a Glance

Purchase Price:

Premium:

Synergies:

Financing:

$33.25 per share

$2.6 billion total consideration, including the assumption of debt

55% to Auxilium’s closing stock price on September 16, 2014, the day

Endo made public its proposal for Auxilium

~$175 million of identified annual cost synergies, including Auxilium’s

previously announced cost restructuring

Full run-rate achieved within first year after closing

Combination of existing cash on hand and committed debt financing to

fund the cash portion of the transaction

Accretion:

Immediately

accretive

post

and

meaningfully

accretive

each

year

thereafter

Consideration:

Option to elect 100% equity, 100% cash or a standard election of

$16.625 cash plus 0.244 shares of Endo International plc for each

Auxilium share owned at closing

Total cash will not exceed 50% of total equity value and equity

consideration will not exceed 75%

Auxilium Snapshot

Specialty biopharmaceutical company with a focus on

developing and commercializing innovative products for

specialist audiences

Leader in men’s healthcare and has strategically expanded

its product portfolio and pipeline in orthopedics,

dermatology and other therapeutic areas

Broad range of first-

and second-line products across

multiple indications with strong R&D capabilities and

pipeline

Portfolio of FDA-approved products in the urology,

orthopedics and other areas in the U.S., and in select

international markets

Ticker:

NASDAQ: AUXL

Headquarters:

Chesterbrook, Pennsylvania

Founded:

1999

Headcount:

639 employees as of 12/31/13*

Revenue Mix

(1)

Testim

XIAFLEX

TESTOPEL

STENDRA

Edex

Other

* Auxilium announced an approximately 30% reduction in headcount in September 2014

(1) – Reported Total Net Revenues for the 12-month period ended June 30, 2014

Endo executing strategic plan to enhance shareholder value

Meeting or exceeding financial targets

Maximizing the growth potential of core businesses

Continued investment in de-risked R&D

Lean and efficient operating model

Pursuing accretive value creating M&A that delivers compelling financial returns and future

organic growth options

Value creating combination

Addition of Auxilium’s XIAFLEX®, STENDRA®

and other products complement Endo’s

branded pharmaceuticals portfolio

Opportunity for XIAFLEX in potential new indications supports long-term organic growth

Combined

company

will

have

broad

range

therapeutic

options

men’s

health

Enhanced operating efficiencies

Combination Aligns with Endo’s Strategic Direction

Combination designed to enhance value for

both Auxilium and Endo shareholders

Paladin Labs for cash and stock in November 2013

Expanded global footprint into Canada and emerging markets

Established Irish domicile for advantaged corporate platform

Boca Pharmacal in August 2013 and DAVA Pharmaceuticals in June 2014

Added significant near-term EBITDA and cash flow from operations to support

future M&A

Expanded generics R&D platform supporting long-term organic growth

Grupo Farmaceutico Somar in April 2014

Added platform for organic growth in emerging markets with established

commercial footprint, manufacturing capabilities and pipeline of

products

Sumavel®

DosePro®

in April 2014

Enabled Endo to leverage commercial capabilities and Ireland-based platform

Demonstrated Record of Value Enhancing Transactions

Auxilium’s FDA-approved products in urology, orthopedics, and other areas

are natural complements to men’s health and pain products in Endo’s

branded pharmaceuticals portfolio

Endo expects to optimize Auxilium’s portfolio of products by leveraging scale,

competencies and resources

Drive increased adoption and continued strong performance for Auxilium’s

XIAFLEX®

and STENDRA®

Support development of XIAFLEX for potential new indications

Optimize Auxilium’s broader portfolio

Combined company will be well positioned to drive organic growth

for branded pharmaceuticals business

Highly complementary portfolio expected to maximize the value of

Auxilium’s commercial products

Accelerating Organic Growth

Select Highlights of Complementary Product Portfolio

Men’s Health / Urology

Orthopedics / Pain

Other Specialty

Testosterone Gel 1%

Authorized Generic

Enhanced near-

and long-term revenue growth profile

Strong margin profile

Immediate and meaningful long-term accretion

Robust financial returns that are well in excess of combined cost of

capital

Enhanced cash flows provide balance sheet flexibility and rapid de-

levering

Deal structure enables continued execution of Endo’s strategy

Enhanced Pro Forma Financial Profile

Annual run-rate operating cost synergy estimated to reach approximately

$175 million within the first 12 months after closing

Leverage platform for more efficient operations, including cost savings in:

Sales and Marketing

R&D

G&A

Driven

complementary

nature

companies’

product

portfolios

Synergies include Auxilium’s reduction in annual operating expenses

previously announced on September 9, 2014

Attractive cost synergies contribute to expected strong value creation

potential and leads to improved operating margins

Significant and Achievable Synergy Opportunities

Combination of existing cash on hand and committed debt

financing from Citi to fund the cash portion of the transaction

Transaction is subject to:

Regulatory approval in the U.S. and certain other jurisdictions

Other customary closing conditions

Expected to close in the first half of 2015

Roadmap to Completion